TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Premenopausal female aged 18 to 50 years old (inclusive) on the day of signing and dating the informed consent form.~2. Has regularly occurring menstrual periods of ≤ 14 days duration with a cycle of 21 to 38 days from the start of 1 menstrual period until the start of the next, by participant history for at least 3 months prior to the first screening visit.~3. Has a diagnosis of uterine fibroids that is confirmed by a transvaginal and/or transabdominal ultrasound performed during the screening period.~4. Has heavy menstrual bleeding associated with uterine fibroids as evidenced by an MBL of ≥ 160 milliliter (mL) during 1 cycle or ≥ 80 mL per cycle for 2 menstrual cycles as measured by the alkaline hematin method during the screening period.~Key Exclusion Criteria:~1. Has transvaginal and/or transabdominal ultrasound during the screening period demonstrating pathology other than uterine fibroids that could be responsible for or contributing to the participant's heavy menstrual bleeding.~2. Has known rapidly enlarging uterine fibroids in the opinion of the investigator.~3. Has a weight that exceeds the weight limit of the DXA scanner or has a condition that precludes an adequate DXA measurement at the lumbar spine and proximal femur.~4. Has a history of or currently has osteoporosis, or other metabolic bone disease, hyperparathyroidism, hyperprolactinemia, hyperthyroidism, anorexia nervosa, or low traumatic (from the standing position) or atraumatic fracture (toe, finger, skull, face and ankle fractures are allowed). A history of successfully treated hyperparathyroidism, hyperprolactinemia, or hyperthyroidism is allowed if the participant's bone mineral density is within normal limits.~5. Has a history of the use of bisphosphonates, calcitonin, calcitriol, ipriflavone, teriparatide, denosumab, or any medication other than calcium and vitamin D preparations to treat bone mineral density loss.~6. Has been a participant in an investigational drug or device study within the 1 month prior to the first screening visit.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Relugolix plus E2/NETA (Group A) (Type: EXPERIMENTAL): Relugolix co-administered with E2/NETA for 24 weeks.
- Relugolix plus Delayed E2/NETA (Group B) (Type: EXPERIMENTAL): Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
- Placebo (Group C) (Type: PLACEBO_COMPARATOR): Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a premenopausal female at the time of Screening.~* Subject has a diagnosis of uterine fibroids documented by a pelvic ultrasound (transabdominal ultrasound/transvaginal ultrasound).~* Subject has heavy menstrual bleeding associated with uterine fibroids as evidenced by menstrual blood loss \> 80 mL during each of two screening menses as measured by the alkaline hematin method.~* Subject has negative urine and/or serum pregnancy test in Screening and just prior to first dose.~* Subject has an adequate endometrial biopsy performed during Screening, the results of which show no clinically significant endometrial pathology.~Exclusion Criteria:~* Subject has screening pelvic ultrasound or saline infusion sonohysterography results that show a clinically significant gynecological disorder.~* Subject has history of osteoporosis or other metabolic bone disease.~* Subject has clinically significant abnormalities in clinical chemistry, hematology, or urinalysis.~* Subject has a history of major depression or post-traumatic stress disorder (PTSD) within 2 years of screening, OR a history of other major psychiatric disorder at any time (e.g., schizophrenia, bipolar disorder).~* Subject is using any systemic corticosteroids for over 14 days within 3 months prior to Screening or is likely to require treatment with systemic corticosteroids during the course of the study. Over the counter and prescription topical, inhaled, intranasal or injectable (for occasional use) corticosteroids are allowed.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 51 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/ NETA) once daily (QD)
- Elagolix (Type: EXPERIMENTAL): Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
- Elagolix + E2/NETA (Type: EXPERIMENTAL): Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have participated in a randomized qualifying study of CP-690,550 for the treatment of rheumatoid arthritis~Vaccine sub-study visit~* Subjects actively participating in Study A3921024 must have completed at least 3 months of continuous 10 mg BID CP-690,550 treatment in A3921024 as defined by \>80% compliance with prescribed dose consumption of CP-690,550 over the previous 3 months.~Exclusion Criteria:~* Serious medical conditions that would make treatment with CP-690,550 potentially unsafe~Vaccine sub-study visit~1. Any documented influenza or pneumococcal infection within the last 3 months prior to randomization in this study~2. Received any vaccine within 1 month prior to randomization in this study~3. Received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of randomization in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-Label Active Treatment Enrolled from Phase 2 (Type: EXPERIMENTAL): Patients enrolling from Phase 2 studies
- Open-Label Active Treatment Enrolled from Phase 3 (Type: EXPERIMENTAL): Patients enrolling from Phase 3 studies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.~* A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.~* Written informed consent obtained from the parent(s)/Legally Acceptable Representative(s) of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Infants who have received a previous dose of hepatitis B immunoglobulin after birth.~Exclusion Criteria:~* Child in care.~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs with the exception of Hepatitis B immunoglobulin since birth. Child is unlikely to remain in the study area for the duration of the study.~* Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Previous vaccination against rotavirus.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Family history of congenital or hereditary immunodeficiency.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness.~* Acute disease and/or fever at the time of enrolment.~* Administration of immunoglobulins (with the exception of HBIG) and/or any blood products since birth or planned administration during the study period.~* Gastroenteritis within 7 days preceding the study vaccine administration.~* Previous confirmed occurrence of Rotavirus gastroenteritis.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- Rotarix Group (Type: EXPERIMENTAL): subjects received 2 oral doses of Rotarix™ vaccine at 2 and 4 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject suffering from generalized prurigo nodularis~* Have demonstrated pruritus intensity during screening~* Male or female who are at least 18 years old at the time of consent~Exclusion Criteria:~* Subject has chronic pruritus resulting from other conditions~* Subject has a history of substance abuse within the past year~* Subject has a known drug allergy to opioids~* Subject is a pregnant or lactating female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- nalbuphine HCl ER 90mg (Type: EXPERIMENTAL): nalbuphine HCl ER tablets 90 mg BID
- nalbuphine HCl ER 180 mg (Type: EXPERIMENTAL): nalbuphine HCl ER tablets 180 mg BID
- Sugar pill (Type: PLACEBO_COMPARATOR): Placebo tablets BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, non-smoking male subjects~* Body Mass Index (BMI) between 19.0 and 28.0 kg/m2, both inclusive~* Body weight max. 100 kg~Exclusion Criteria:~* A history or presence of cancer, diabetes, or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, psychiatric diseases or other major diseases~* Carrier of Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies~* Positive result of test for HIV (Human Immunodeficiency Virus) antibodies~* Any clinically significant abnormal haematology or biochemistry screening tests, as judged by the physician~* Clinically significant abnormal ECG (ElectroCardioGram) at screening as evaluated by the physician~* A significant history of alcoholism or drug/chemical abuse, or who has a positive result in the urine drug/alcohol screen, or who consumes more than 28 units of alcohol per week (one unit of alcohol equals about 250 ml of beer or lager, 1 glass of wine, or 20 ml of spirits)~* Habitual smoking, i.e daily smoking or more than 7 cigarettes/week~* Mental incapacity or language barriers which preclude adequate understanding or cooperation, who are unwilling to participate in the trial, or who in the opinion of their general practitioner or the Investigator should not participate in the trial~* Surgery or trauma with significant blood loss within the last 2 months prior to dosing

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Norditropin® SimpleXx® 0.02 mg/kg + NNC126-0083 (Type: EXPERIMENTAL): None
- Norditropin® SimpleXx® 0.04 mg/kg + NNC126-0083 (Type: EXPERIMENTAL): None
- Norditropin® SimpleXx® 0.02 mg/kg + placebo (Type: PLACEBO_COMPARATOR): None
- Norditropin® SimpleXx® 0.04 mg/kg + placebo (Type: PLACEBO_COMPARATOR): None
- NNC126-0083 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study Comparing Dental Plaque and Gingivitis Reduction After Using One of Three Oral Hygiene Multi-component Regimens (Using of a Manual Toothbrush, a Toothpaste and a Mouthwash)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects, ages 18-70, inclusive.~2. Availability for the six-month duration of the study.~3. Good general health.~4. Minimum of 20 uncrowned permanent natural teeth (excluding third molars).~5. Initial gingivitis index of at least 1.0 as determined by the use of the Loe and Silness Gingival Index.~6. Initial plaque index of at least 1.5 as determined by the use of the Quigley and Hein Plaque Index (Turesky Modification).~7. Signed Informed Consent Form.~Exclusion Criteria:~1. Presence of orthodontic bands.~2. Presence of partial removable dentures.~3. Tumor(s) of the soft or hard tissues of the oral cavity.~4. Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone).~5. Five or more carious lesions requiring immediate restorative treatment.~6. Use of antibiotics any time during the one month prior to entry into the study.~7. Participation in any other clinical study or test panel within the one month prior to entry into the study.~8. Pregnant women or women who are breast feeding.~9. Dental prophylaxis received in the past two weeks prior to baseline examinations.~10. History of allergies to oral care/personal care consumer products or their ingredients.~11. On any prescription medicines that might interfere with the study outcome.~12. An existing medical condition which prohibits eating or drinking for periods up to 4 hours.~13. History of alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Toothpaste (Type: ACTIVE_COMPARATOR): Triclosan/fluoride toothpaste
- Toothpaste + mouthwash (Type: ACTIVE_COMPARATOR): stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
- Fluoride only Toothpaste + mouthwash (Type: PLACEBO_COMPARATOR): Fluoride only toothpaste + Fluoride only Mouthwash

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Ability of parents or legal guardians to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local subject privacy regulations. Subjects will provide assent in addition to the parent or legal guardian, as appropriate, as per local regulations.~* Must have a body weight of ≥30 kg at Screening and Day 1.~* Must have a diagnosis of RRMS according to McDonald criteria for MS (2010) \[Polman 2011\] and International Pediatric Multiple Sclerosis (MS) Study Group criteria for pediatric MS (2013) \[Krupp 2013\].~Key Exclusion Criteria:~* Primary progressive, secondary progressive, or progressive relapsing MS (as defined by \[Lublin and Reingold 1996\]). These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Subjects with these conditions may also have superimposed relapses but are distinguished from relapsing-remitting subjects by the lack of clinically stable periods or clinical improvement.~* Disorders mimicking MS, such as other demyelinating disorders (e.g., acute disseminated encephalomyelitis), systemic autoimmune disorders (e.g., Sjögren disease, lupus erythematosus, and neuromyelitis optica), metabolic disorders (e.g., dystrophies), and infectious disorders.~* History of severe allergic or anaphylactic reactions or known drug hypersensitivity to dimethyl fumarate or fumaric acid esters.~NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- BG00012 (Type: EXPERIMENTAL): Oral BG00012 120 mg twice daily (BID) for the first 7 days followed by 240 mg BID for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Investigation of Stem Cells in Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males~* 60 years or over~* Unilateral ischemic stroke involving subcortical white matter or Basal Ganglia 6 months to 5 years before entry~* NIHSS score minimum 6 with hemiparesis (2 or more for motor arm and leg)~* Neurologically stable for 2 m~* modified Rankin score of 2-4~* Fit for general anesthesia, neurosurgery~* Capacity to consent~* Infarct at least 1cm diameter~Exclusion Criteria:~* Structural brain vascular lesions requiring surgery or increasing the risk of stereotaxic implantation~* Unstable medical conditions with expected survival \<12 months~* Any medical condition that would impair participation (eg progressive neurological disorders, mental illness)~* Major surgery within 30 days~* Previous allogeneic tissue transplant~* MMSE \< 24~* Epilepsy~* Coagulation disorders or anticoagulant treatment that cannot be interrupted~* Stimulants, botox, tamoxifen~* Contraindications to MRI

- Gender: MALE
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- CTX0E03 DP (Type: EXPERIMENTAL): human neural stem cell product, once only injection, increasing doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ability and willingness to participate in the study and to sign and give informed consent~* Confirmed H. pylori infection and with previous treatment experience~Exclusion Criteria:~* Less than 18 years old~* With previous gastric surgery~* Previous history of tuberculosis~* Major systemic diseases~* Pregnancy or lactation~* Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tetracycline Bismuth Quadruple Therapy (Type: ACTIVE_COMPARATOR): Esomeprazole 20mg bid, Bismuth Potassium Citrate 300mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
- rifabutin triple therapy (Type: EXPERIMENTAL): Esomeprazole 20mg bid, amoxicillin 1000mg bid, rifabutin 150mg bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete